VISEN Pharmaceuticals (HKG:2561)
Hong Kong
· Delayed Price · Currency is HKD
32.56
+1.06 (3.37%)
Mar 10, 2026, 3:59 PM HKT
VISEN Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 |
| Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Other Revenue | 0.84 | 2.78 | -1.67 | -2.3 |
| Revenue | 0.84 | 2.78 | -1.67 | -2.3 |
| Gross Profit | 0.84 | 2.78 | -1.67 | -2.3 |
| Selling, General & Admin | 102.84 | 86.43 | 79.94 | 177.45 |
| Research & Development | 98.23 | 90.52 | 57.69 | 179.55 |
| Operating Expenses | 201.06 | 176.96 | 137.63 | 357 |
| Operating Income | -200.22 | -174.18 | -139.3 | -359.29 |
| Interest Expense | -0.11 | -0.16 | -0.32 | -0.62 |
| Interest & Investment Income | 7.75 | 6.77 | 11.15 | 5.57 |
| Currency Exchange Gain (Loss) | -6.47 | 2.69 | 4.71 | 79.78 |
| Other Non Operating Income (Expenses) | -17.74 | -17.37 | -16.28 | -14.3 |
| EBT Excluding Unusual Items | -216.79 | -182.24 | -140.05 | -288.86 |
| Gain (Loss) on Sale of Assets | - | - | -0.24 | -0.1 |
| Other Unusual Items | - | - | -109.28 | - |
| Pretax Income | -216.79 | -182.24 | -249.57 | -288.97 |
| Net Income | -216.79 | -182.24 | -249.57 | -288.97 |
| Net Income to Common | -216.79 | -182.24 | -249.57 | -288.97 |
| Shares Outstanding (Basic) | 97 | 94 | 94 | - |
| Shares Outstanding (Diluted) | 97 | 94 | 94 | - |
| EPS (Basic) | -2.24 | -1.95 | -2.67 | - |
| EPS (Diluted) | -2.24 | -1.95 | -2.67 | - |
| Free Cash Flow | -180.36 | -140.98 | -271.83 | -248.03 |
| Free Cash Flow Per Share | -1.86 | -1.51 | -2.90 | - |
| Gross Margin | 100.00% | 100.00% | - | - |
| Operating Margin | -23807.37% | -6272.16% | - | - |
| Profit Margin | -25777.76% | -6562.55% | - | - |
| Free Cash Flow Margin | -21445.66% | -5076.52% | - | - |
| EBITDA | -200.21 | -173.46 | -137.79 | -357.55 |
| D&A For EBITDA | 0.01 | 0.72 | 1.51 | 1.74 |
| EBIT | -200.22 | -174.18 | -139.3 | -359.29 |
Source: S&P Capital IQ. Standard template.
Financial Sources.